Sermorelin
Also known as GHRH (1-29)
Studied for: gHRH fragment
Sermorelin is a synthetic peptide comprising the first 29 amino acids of growth-hormone-releasing hormone, the shortest fragment retaining full activity at the GHRH receptor. Research examines its role as a growth-hormone secretagogue acting on pituitary somatotrophs.
Last reviewed September 26, 2026
How it is thought to work
Research investigates sermorelin for binding to the GHRH receptor on pituitary somatotrophs, studied for cAMP-mediated signaling that supports pulsatile growth-hormone release while leaving somatostatin feedback intact.
- GHRH ReceptorStudied for activation of the pituitary GHRH receptor and the downstream cAMP and PKA signaling cascade.
- Pulsatile ReleaseExplored for preserving the natural pulsatile pattern of growth-hormone secretion rather than a constant signal.
- Feedback IntactStudied as an upstream signal that remains subject to somatostatin and IGF-1 negative feedback.
- Route studied
- Subcutaneous
- Receptor class
- GHRH-R
- Research status
- Approved analog
Published reviews describe the clinical use of Sermorelin in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.
Research
What the research covers
What research examines
- Diagnosis of idiopathic growth hormone deficiency in children
- Treatment of idiopathic growth hormone deficiency in children
- Adult-onset growth hormone insufficiency
- Recurrent glioma (exploratory research)
- Analytical detection and serum stability of GHRH analogs
- PEGylation of GHRH analogues
Reported effects in studies
- Adverse events are not summarized in the cited studies
- Human safety data outside pediatric growth hormone deficiency research are limited
- Synthetic GHRH analogs are targets of anti-doping detection methods
- Enzymatic and serum degradation of GHRH-related peptides has been characterized
Studied range
What research protocols have used
Research protocols have used 200–500 mcg per administration, 5 days per week (evening), in 12-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorStudies
Cited research
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999 · PMID 18031173
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging · 2006 · PMID 18046908
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine · 2021 · PMID 33842627
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
Drug testing and analysis · 2021 · PMID 34665524
- In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
Biomedical chromatography : BMC · 2023 · PMID 37688464
FAQ
Questions about Sermorelin
Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that targets the GHRH receptor (GHRH-R). It has been reviewed in the literature for its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and it has been discussed as an approach to adult-onset growth hormone insufficiency. CoreX supplies Sermorelin for laboratory research use only.
Sermorelin is classed as a GHRH receptor (GHRH-R) agonist. It binds the receptor through which endogenous growth hormone-releasing hormone signals the pituitary to release growth hormone. Because it acts upstream of growth hormone rather than supplying the hormone itself, it has been discussed in research as an alternative approach to studying growth hormone insufficiency. Research protocols have typically used the subcutaneous route.
The main body of published work concerns the diagnosis and treatment of idiopathic growth hormone deficiency in children, along with commentary on adult-onset growth hormone insufficiency. Exploratory research has examined Sermorelin as a potential agent in recurrent glioma. Analytical studies have addressed detection of synthetic GHRH analogs, their enzymatic and serum stability, and PEGylation of GHRH analogues as a strategy to modify their properties.
Adverse events are not summarized in the cited studies, and human safety data outside pediatric growth hormone deficiency research are limited. Reviews of peptide use in sport and bodybuilding discuss GHRH-related compounds in the context of doping, and synthetic GHRH analogs are targets of anti-doping detection methods. Stability studies have characterized how GHRH-related peptides degrade in enzymatic and serum conditions, which is relevant to sample handling in laboratory work.
Research protocols have used 200–500 mcg per administration, 5 days per week in the evening, in 12-week blocks followed by 4 weeks off, via the subcutaneous route. These figures describe what published or reported research protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about Sermorelin
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- CJC-1295 vs SermorelinCJC-1295 and Sermorelin are both growth-hormone-releasing hormone (GHRH) analogs that act on the pituitary GHRH receptor. CJC-1295 without DAC, also called modified GRF 1-29, is described in research as a short-acting analog; lacking a drug affinity complex keeps its action brief, which research associates with preserving natural pulsatile growth hormone release. Its human evidence is early, drawn mainly from reviews, anti-doping detection work, and a small trial of the long-acting DAC form. Published reviews describe clinical use of Sermorelin in diagnosing and treating idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.
- Ipamorelin vs SermorelinIpamorelin and Sermorelin are both peptides studied for stimulating growth hormone release, but they act through different receptors. Ipamorelin is a selective growth hormone secretagogue described as a ghrelin receptor (GHS-R1a) agonist, examined for releasing growth hormone with minimal effect on cortisol or prolactin. Its primary studies are animal studies of growth hormone release and bone growth. Sermorelin is a synthetic GHRH analog that acts at the GHRH receptor (GHRH-R). Published reviews describe its clinical use in the diagnosis and treatment of idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency. Human safety data are limited for Ipamorelin, and for Sermorelin outside pediatric research.